Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 43 articles: HTML format

Single Articles

September 2025
1. HAAS JS, Todd KW, Mclerran D, Tiro JA, et al
   Gaps in care across the cancer screening continuum for cervical, colorectal and lung cancer.
   J Natl Cancer Inst. 2025 Sep 10:djaf248. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. FAN Y, Jin R, Monterroza L, Liu X, et al
   Suppression of LKB1-mutant lung adenocarcinoma by natural killer cells from females.
   J Natl Cancer Inst. 2025;117:1858-1867.
   PubMed     Abstract available
   
   
   August 2025
3. PATON EL, Cetnar JP, Freeman-Daily J, Feldman J, et al
   Landscape assessment of patient-reported outcome item coverage of tyrosine kinase inhibitor-associated adverse events.
   J Natl Cancer Inst. 2025;117:1664-1672.
   PubMed     Abstract available
   
   
   
4. FULLER S, Alexeeff S, Caan B, Goncalves MD, et al
   Early identification of weight loss trajectories in advanced cancer and associations with survival.
   J Natl Cancer Inst. 2025;117:1729-1732.
   PubMed     Abstract available
   
   
   July 2025
5. 
   Correction to: Obesity-Specific Improvement of Lung Cancer Outcomes and Immunotherapy Efficacy with Metformin.
   J Natl Cancer Inst. 2025 Jul 28:djaf184. doi: 10.1093.
   PubMed    
   
   
   
6. ABURAKI R, Fujiwara Y, Haketa S, Horita N, et al
   Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis.
   J Natl Cancer Inst. 2025 Jul 24:djaf190. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. LAVERY JA, Chen Y, Panageas KS, Wang Y, et al
   Unveiling non-small cell lung cancer treatment effect heterogeneity: a comparative analysis of statistical methods.
   J Natl Cancer Inst. 2025 Jul 10:djaf176. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. XIA L, Pu Q, Kang R, Mei J, et al
   Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study).
   J Natl Cancer Inst. 2025;117:1474-1484.
   PubMed     Abstract available
   
   
   
9. FAN Q, Dong W, Schafer EJ, Wagle NS, et al
   Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States.
   J Natl Cancer Inst. 2025;117:1506-1511.
   PubMed     Abstract available
   
   
   June 2025
10. ZHANG J, Wang S, Li T, Liu X, et al
    RE: Efficacy and safety of personalized optimal programmed cell death 1 ligand combinations in advanced non-small cell lung cancer: a network meta-analysis.
    J Natl Cancer Inst. 2025 Jun 6:djaf132. doi: 10.1093.
    PubMed    
    
    
    May 2025
11. MCWILLIAM A, Marshall D, Kerns SL, Barnett GC, et al
    Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
    J Natl Cancer Inst. 2025;117:1018-1026.
    PubMed     Abstract available
    
    
    March 2025
12. ZHOU P, Cui J, Sun R, Liu X, et al
    RE: Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake.
    J Natl Cancer Inst. 2025 Mar 27:djaf081. doi: 10.1093.
    PubMed    
    
    
    
13. MILDER CM, Cahoon EK, Schonfeld SJ, Preston DL, et al
    Sex-specific radiation-associated lung cancer mortality risks as impacted by smoking among US radiologic technologists.
    J Natl Cancer Inst. 2025 Mar 20:djaf064. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. NOGUEIRA LM, Yabroff KR, Yates E, Shultz JM, et al
    Facility exposure to wildfire disasters and hospital length of stay following lung cancer surgery.
    J Natl Cancer Inst. 2025 Mar 11:djaf040. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
15. HU P, Prorok PC, Katki HA
    Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.
    J Natl Cancer Inst. 2025;117:303-311.
    PubMed     Abstract available
    
    
    January 2025
16. KANAYA N, Seddiq W, Chen KS, Kajiwara Y, et al
    Engineered allogeneic stem cells orchestrate T lymphocyte driven immunotherapy in immunosuppressive leptomeningeal brain metastasis.
    J Natl Cancer Inst. 2025 Jan 22:djaf006. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al
    Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
    J Natl Cancer Inst. 2025;117:188-197.
    PubMed     Abstract available
    
    
    
18. TUMINELLO S, Turner WM, Untalan M, Ivic-Pavlicic T, et al
    Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake.
    J Natl Cancer Inst. 2025;117:112-119.
    PubMed     Abstract available
    
    
    November 2024
19. GOMEZ SL, DeRouen M, Chen MS Jr, Wakelee H, et al
    Elevated risk of lung cancer among asian American females who have never smoked: an emerging cancer disparity.
    J Natl Cancer Inst. 2024 Nov 20:djae299. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. SMITH RJ JR, Zollo R, Kalvapudi S, Vedire Y, et al
    Obesity-Specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin.
    J Natl Cancer Inst. 2024 Nov 19:djae295. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
21. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    PubMed     Abstract available
    
    
    
22. CHU X, Tian W, Ning J, Zhou R, et al
    Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis.
    J Natl Cancer Inst. 2024;116:1571-1586.
    PubMed     Abstract available
    
    
    September 2024
23. PROSPER AE, Lin Y, Aberle DR
    Lung cancer screening with low-dose computed tomography-where do we go from here?
    J Natl Cancer Inst. 2024 Sep 16:djae197. doi: 10.1093.
    PubMed    
    
    
    August 2024
24. LIU Q, Medina HN, Koru-Sengul T, Rodriguez E, et al
    Intra-Ethnic and Geographic Disparities in Stage at Diagnosis for Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2024 Aug 21:djae199. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available
    
    
    June 2024
26. ZHANG EY, Cheung LC, Katki HA, Graubard BI, et al
    The risk and benefit profiles of US eligible lung cancer screening attendees vs. non-attendees.
    J Natl Cancer Inst. 2024 Jun 27:djae148. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. HENDERSON LM, Durham DD, Gruden J, Pritchard M, et al
    Comparing characteristics of individuals screened for lung cancer with 2021 versus 2013 USPSTF recommendations.
    J Natl Cancer Inst. 2024 Jun 24:djae141. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. WU X, Zhang B
    RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 8:djae130. doi: 10.1093.
    PubMed    
    
    
    
29. TAKI T, Ishii G
    RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 7:djae131. doi: 10.1093.
    PubMed    
    
    
    
30. SCHUZ J, Kovalevskiy E, Olsson A, Moissonnier M, et al
    Cancer mortality in chrysotile miners and millers, Russian Federation: main results (Asbest Chrysotile Cohort-Study).
    J Natl Cancer Inst. 2024;116:866-875.
    PubMed     Abstract available
    
    
    
31. UPRETY D, Seaton R, Hadid T, Mamdani H, et al
    Racial and socioeconomic disparities in survival among patients with metastatic Non-Small cell lung cancer.
    J Natl Cancer Inst. 2024 Jun 3:djae118. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
32. FUCITO LM, Palmer AM, Baldassarri SR
    A new perspective on mitigating lung cancer risks through smoking cessation and reduction.
    J Natl Cancer Inst. 2024 Mar 18:djae044. doi: 10.1093.
    PubMed    
    
    
    
33. NAGASAKI Y, Taki T, Nomura K, Tane K, et al
    Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    J Natl Cancer Inst. 2024 Mar 8:djae053. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
34. MOEN EL, Schmidt RO, Onega T, Brooks GA, et al
    Association between a network-based physician linchpin score and cancer patient mortality: a SEER-Medicare analysis.
    J Natl Cancer Inst. 2024;116:230-238.
    PubMed     Abstract available
    
    
    
35. MEERNIK C, Raveendran Y, Kolarova M, Rahman F, et al
    Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.
    J Natl Cancer Inst. 2024 Feb 6:djae026. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2024
36. GUTIERREZ-TORRES DS, Kim S, Albanes D, Weinstein SJ, et al
    Changes in smoking use and subsequent lung cancer risk in the ATBC study.
    J Natl Cancer Inst. 2024 Jan 25:djae012. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2023
37. SHIELS MS, Graubard BI, McNeel TS, Kahle L, et al
    Trends in smoking-attributable and smoking-unrelated lung cancer death rates in the U.S., 1991-2018.
    J Natl Cancer Inst. 2023 Dec 9:djad256. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. BILLINGY NE, Tromp VNMF, Aaronson NK, Hoek RJA, et al
    Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial.
    J Natl Cancer Inst. 2023;115:1515-1525.
    PubMed     Abstract available
    
    
    
39. ZUMSTEG ZS, Luu M, Rosenberg PS, Elrod JK, et al
    Global epidemiologic patterns of oropharyngeal cancer incidence trends.
    J Natl Cancer Inst. 2023;115:1544-1554.
    PubMed     Abstract available
    
    
    November 2023
40. LEHRER S, Rheinstein PH
    Re: Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancers.
    J Natl Cancer Inst. 2023;115:1427-1428.
    PubMed    
    
    
    
41. LU K, Wang HC, Tu YC, Chang CC, et al
    Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer.
    J Natl Cancer Inst. 2023;115:1383-1391.
    PubMed     Abstract available
    
    
    
42. EVANS JV, Suman S, Goruganthu MUL, Tchekneva EE, et al
    Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.
    J Natl Cancer Inst. 2023;115:1404-1419.
    PubMed     Abstract available
    
    
    September 2023
43. KHODAYARI MOEZ E, Warkentin MT, Brhane Y, Lam S, et al
    Circulating proteome for pulmonary nodule malignancy.
    J Natl Cancer Inst. 2023;115:1060-1070.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.